公开(公告)号：US20180119227A1

公开(公告)日：2018-05-03

申请号：US15724309

申请日：2017-10-04

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Zvi LIVNEH ,  Tamar PAZ-ELIZUR

IPC: C12Q1/6886 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  G01N33/57423

Abstract: Methods and kits for determining a risk of a subject, or subjects for developing lung cancer is disclosed. The method comprises determining a level of catalytic activity of N-methylpurine DNA glycosylase (MPG), or apurinic/apyrimidinic endonuclease 1 (APE1), or both, or MPG and 8-oxoguanine DNA glycosylase (OGG1), or MPG and APE1 and OGG1 in peripheral blood cells of a subject, wherein levels of MPG above a predetermined reference value, or APE1 or OGG1, or a integrated DNA repair score below a predetermined reference value is indicative of an increased risk of developing lung cancer.

公开(公告)号：US20220170939A1

公开(公告)日：2022-06-02

申请号：US17670467

申请日：2022-02-13

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Zvi LIVNEH ,  Tamar PAZ-ELIZUR

IPC: G01N33/574 ,  G01N33/68 ,  A61K31/7088

Abstract: A method of selecting a treatment for a subject having cancer is disclosed. The method comprises: (a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and (b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of said DNA repair enzyme as compared to the catalytic activity of said DNA repair enzyme in a biological sample of a healthy subject.